李家平，广州医科大学附属肿瘤医院，院长，党委副书记，主任医师，博士生导师
基本情况简介：中山大学医学博士，美国南加州大学博士后，2011韩国Asan医学中心、2013瑞典卡洛琳斯卡医学院访问学者。
李家平教授深耕于肿瘤介入学临床医教研一线27年，擅长肿瘤与肝硬化门脉高压症的微创介入治疗，特别是对原发与转移性肝癌、肺癌、胆管癌、胰腺癌、膀胱癌、卵巢癌、宫颈癌，肝母与肾母细胞瘤、血管畸形的介入诊疗（包括经动脉灌注化疗与栓塞、氩氦刀冷冻、射频、微波消融、粒子与支架植入、药盒埋置）以及区域化疗、分子靶向与免疫治疗，并在肝硬化门脉高压症TIPS术、颈动脉体瘤栓塞术、胆道恶性梗阻导管射频消融联合支架植入术与外周血管闭塞性疾病开通术方面也积累了丰富的诊疗经验，多项医疗技术处于国内领先水平。
李家平教授先后主持国家自然科学基金项目 7 项、省部级重大科研专项 13 项、国家专利 12 项，在 Journal of Clinical Oncology、Gut、Radiology、Journal of Hepatology、Nucleic Acids Research、PNAS、 Liver Cancer、Moleculartherapy、CVIR、JVIR等国际著名杂志上发表 SCI 论著 140余篇，他引3000余次，最高单篇IF: 50.7 分。主编人卫版《肝癌微创介入治疗学》, 主持《中国胆道恶性梗阻腔内射频消融治疗专家共识》, 主笔《中国肝癌TACE 临床实践指南》, 参编多个共识与指南，分别荣获中华医学科技奖、中国抗癌协会科技奖、广东省科技进步奖、广东医学科技奖、亚洲肿瘤消融大会 (ACTA) 杰出学术成就奖、国际冷冻治疗学会学术成就奖等多个奖项。
社会任职：
1.亚洲冷冻治疗学会主席
2.中华放射学分会全国委员兼介入学组副组长
3.广东省医学会介入医学分会主任委员
4.广东省卫健委综合介入专业质控中心主任
5.国家卫健委综合介入质控中心肿瘤血管组副组长
6.中国医师协会介入医师分会常委兼数智介入诊疗专委会主任委员
7.广东省临床医学学会肿瘤介入学专委会主任委员
8.中国抗癌协会微创治疗专委会副主任委员
9.中国CSCO介入放射专委会副主任委员
10.广东省医师协会介入医师分会副主任委员
11.国际肝胆胰学会微创介入治疗委员会副主任委员
12.亚太影像引导下肿瘤消融协会常务理事
联系方式:E-mail：lijiap@mail.sysu.edu.cn
研究领域：
1.基于介入的肝癌基因与免疫治疗
2.肿瘤的数字与智能化介入治疗
3.肿瘤免疫微环境调控与人肝癌类器官构建
4.肿瘤抗血管生成的调控机制
5.经颈静脉肝内门体静脉分流术（TIPS）的临床与基础研究
6.肿瘤的物理消融与放射粒子近距离治疗的临床研究
科研项目：
1.2025年人工智能医疗器械创新任务揭榜挂帅项目，揭榜方向：智能手术机器人产品，2026.01-2029.12，肝癌穿刺消融多智能体协作手术机器人。李家平（主持）
2.项目批准号：82572337，国家自然科学基金面上项目，2026.01-2029.12，TACE治疗后HCC组蛋白乳酸化修饰促进TREM2+TAM浸润的机制研究。49万元，李家平（主持）
3.项目编号：2025B1111020001，广东省重点领域研发计划，2025.01.01-2030.01.01，肝癌穿刺消融多智能体协作手术机器人的研发及产业化。1600万元，李家平（主持）
4.项目批准号：82372059，国家自然科学基金面上项目，2024.01-2027.12，TREM2+肿瘤相关巨噬细胞在肝细胞癌TACE治疗后的免疫抑制机制。48万元，李家平（主持）
5.项目批准号：2023P-TS30，广州地区临床特色技术项目，2023.01-2025.12，经皮胆道腔内射频消融在恶性胆道梗阻中的应用。25万元，李家平（主持）
6.项目批准号：82172036，国家自然科学基金面上项目，2022.01-2025.12，OPN敲除的新型人肝癌类器官外泌体对TACE术后HCC复发转移与肿瘤免疫微环境的双重作用机制。55万元，李家平（主持）
7.项目批准号：2020B0101130016，广东省重大科技计划项目，2021.01-2022.12，基于5G网络的智慧介入诊疗关键技术研究。500万元，李家平（主持）
8.项目批准号：202103000021，广州市重点研发项目，2021.05-2024.05，基于5G与区块链的肿瘤介入智慧诊疗示范应用体系研究。100万元，李家平（主持）
9.项目批准号：81971719 ，国家自然科学基金面上项目，2020.01-2023.12 ，LncRNA通过MAT1A/MAT2A对TACE术后肝细胞癌OPN信号通路的调控机制。55万元，李家平（主持）
10.项目批准号：81671797，国家自然科学基金面上项目，2017年01月-2020年12月， MAT1A/MAT2A对TACE术后肝细胞癌OPN信号通路的调控机制。60万元，李家平（主持）
11.项目批准号：2017B030308006，广东省重大科技专项，2017年01月-2020年12月，基于大数据处理技术的恶性肿瘤治疗与康复服务支撑平台。300万元，李家平（主持）
12.项目批准号：201704020144，广州市重大科技攻关计划项目， 2017年01月-2019年12月，基于移动互联网的恶性肿瘤精准服务平台关键技术研发与应用。200万元，李家平（主持）
13.项目批准号：81371653，国家自然科学基金面上项目，2014年01月-2017年12月，索拉非尼联合TACE治疗肝癌中通过整合素avβ3对血管生成的调控机制。75万元，李家平（主持）
14.项目批准号：81171441，国家自然科学基金面上项目，2012年01月-2015年12月，经肝动脉导入MAT1A基因和MAT2A短发夹RNA协同抗肝癌的作用机制。60万元，李家平（主持）
代表性论著：
1.Haikuan Liu* Wenzhe Fan,*, HaiqingLi, Liangliang Qiao, ZhilongLiu, Bowen Zhu, Jian Guo, Kun Huang, Yiyang Tang, Jie Wen, Mino Xue, Yanqin W, Yue Zhao, YangJiang, Kangshou Liu, Junjie Liang, Mingrong Cao, Jiaping Li#. ldarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase lV Trial. Radiology (IF:18.9). 2025 May;315(2):e242315.
2.Xiaokai Zhang*, Xiujiao Deng*, Jizhou Tan*, Haikuan Liu, Hong Zhang, Chengzhi Li, Qingjun Li , Jinxue Zhou#, Zeyu Xiao#, Jiaping Li#. Idarubicin-loaded degradable hydrogel for TACE therapy enhances anti-tumor immunity in hepatocellular carcinoma. MATER TODAY BIO(IF:8.7). 2024 Nov 23:29:101343.
3.Kun Huang*, Haikuan Liu*, Yanqin Wu*, Wenzhe Fan, Yue Zhao, Miao Xue, Yiyang Tang, Shi-Ting Feng#, Jiaping Li#. Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors. Radiologia Medica (IF:9.7). 2024 Nov;129(11):1597-1610.
4.Guixiong Zhang*, Yitai Xiao*, Hang Liu, Yanqin Wu, Miao Xue, Jiaping Li#. Integrated machine learning screened glutamine metabolism-associated biomarker SLC1A5 to predict immunotherapy response in hepatocellular carcinoma. Immunobiology(IF:2.5). 2024 Sep;229(5):152841.
5.Wenzhe Fan*, Bowen Zhu*, Shuling Chen*, Yanqin Wu*, Xiao Zhao*, Liangliang Qiao, Zhen Huang, Rong Tang, Jinghua Chen, Wan Yee Lau, Minshan Chen, Jiaping Li, Ming Kuang#, Zhenwei Peng#. Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.JAMA Onco l(IF:22.5).2024 Aug 1;10(8):1047-1054.doi: 10.1001/jamaoncol.2024.1831.
6.Wenzhe Fan*, Xinlin Zheng*, Xiao Zhao*, Bowen Zhu, Yanqin Wu, Miao Xue, Rong Tang, Zhen Huang, Liangliang Qiao, Mingjian Lu, Yiyang Tang, Jian Wu#, Jiaping Li#. DEB-TACE versus cTACE for unresectable HCC with B1-type bile duct invasion after successful biliary drainage: A propensity score matching analysis. Cancer Medicine(IF:2.9). 2024 Jul;13(13):e7419.
7.Zhenwei Peng#*, Wenzhe Fan*, Zelong Liu*, Han Xiao*, Jian Wu*, Rong Tang, Jianfei Tu, Liangliang Qiao, Fuxi Huang, Wenxuan Xie, Wenquan Zhuang, Wenbo Guo, Shaoqiang Li, Yunpeng Hua, Shunli Shen, Qiang He, Dongming Li, Jiaping Li, Ming Kuang#.Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial.JAMA Surg(IF:15.7).2024 Jun 1;159(6):616-624.doi: 10.1001/jamasurg.2024.0506.
8.Guixiong Zhang*, Yitai Xiao*, Jizhou Tan, Hang Liu, Wenzhe Fan, Jiaping Li#. Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. Journal of Translational Medicine (IF:6.1). 2024 Jun 6;22(1):543.
9.Hongyu Wang*, Huijie Huang*, Ting Liu, Yaoming Chen, Jinwei Li, Min He, Jianxin Peng, Enyu Liang, Jiaping Li#, Wendao Liu#. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study. Front Immunol (IF:7.3). 2024 Feb 9:15:1325330.doi: 10.3389/fimmu.2024.1325330. eCollection 2024.
10.Kun Huang, Yanqin Wu, Wenzhe Fan, Yue Zhao, Miao Xue, Haikuan Liu, Yiyang Tang, Jiaping Li#; Identification of BRD7 by whole-exome sequencing as a predictor for intermediate-stage hepatocellular carcinoma in patients undergoing TACE; J Cancer Res Clin Oncol (IF: 2.7); 2023 Oct;149(13):11247-11261
11.Zhenwei Peng*, Wenzhe Fan*, Bowen Zhu*, Guoying Wang, Junhui Sun, Chengjiang Xiao, Fuxi Huang, Rong Tang, Yu Cheng, Zhen Huang, Yuchuang Liang, Huishuang Fan, Liangliang Qiao, Fuliang Li, Wenquan Zhuang, Baogang Peng, Jiping Wang, Jiaping Li#, Ming Kuang#, Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH) , J Clin Oncol(IF=45.3),2023 Jan 1;41(1):117-127.
12.Zhengyu Zou*, Zhun Lin, Chenglin Wu, Jizhou Tan, Jie Zhang, Yanwen Peng, Kunsong Zhang, Jiaping Li#, Minhao Wu#, Yuanqing Zhang#, Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients,Advanced Science(IF=15.1),2023 Jul 23;e2302640.
13.Jizhou Tan*, Ting Liu*, Wenzhe Fan*, Jialiang Wei, Bowen Zhu, Yafang Liu, Lingwei Liu, Xiaokai Zhang, Songling Chen, Haibiao Lin, Yuanqing Zhang, Jiaping Li#,Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1highCD11b+ cells elimination in hepatocellular carcinoma,Acta Pharm Sin B（Acta Pharmaceutica Sinica B）(IF=14.5),2023 Feb;13(2):632-647.
14.Wenzhe Fan*, Bowen Zhu*, Shufan Yue*, Xinlin Zheng, Guosheng Yuan, Lei Yu , Wanchang Huang, Shugui Huang , Wenjiang Wei , Fuliang Li, Zhen Huang , Rong Tang , Huishuang Fan , Zhuoyong Li , Liangliang Qiao , Fuxi Huang , Yu Cheng , Yingqiang Zhang , Yanqin Wu, Xinhua Zou, Miao Xue, Hongyu Wang, Jiaping Li#, Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study,EUROPEAN RADIOLOGY(IF=5.90),2023 Apr;33(4):2809-2820.
15.Xiaokai Zhang*, Jie Wen*, Guixiong Zhang, Wenzhe Fan, Jizhou Tan, Haikuan Liu, Jiaping Li#, Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma,Translational Oncology(IF=5.0),2023 Jan;27:101600.Epub 2022 Dec 5.
16.Wenzhe Fan*, Bowen Zhu*, Shufan Yue, Xinlin Zheng, Xinhua Zou, Fuliang Li, Liangliang Qiao, Yanqin Wu, Miao Xue, Hongyu Wang, Yiyang Tang, Jiaping Li#, Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis,Cancer Medicine(IF=4.711),2023 Jan;12(1):61-72.
17.Wenzhe Fan*, Bowen Zhu*, Xinlin Zheng*, Shufan Yue, Mingjian Lu, Huishuang Fan, Liangliang Qiao, Fuliang Li, Guosheng Yuan, Yanqin Wu, Xinhua Zou, Hongyu Wang, Miao Xue, Jiaping Li#, Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization,JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY(IF=3.6),2023 May;149(5):1873-1882.
18.Jizhou Tan*, Wenzhe Fan*, Ting Liu*, Bowen Zhu, Yafang Liu, Shutong Wang, Jian Wu, Jun Liu, Fan Zou, Jialiang Wei, Lingwei Liu, Xiaokai Zhang, Jialang Zhuang, Yi Wang, Haibiao Lin, Xianzhang Huang, Songling Chen, Ming Kuang#, Jiaping Li#,TREM2+ macrophages suppress CD8+ T cell infiltration after transarterial chemoembolization in hepatocellular carcinoma ,Journal of Hepatology(IF=30.083), 2023 Jul;79(1):126-140
19.Guixiong Zhang*, Yitai Xiao*, Xiaokai Zhang, Wenzhe Fan, Yue Zhao, Yanqin Wu, Hongyu Wang, Jiaping Li#. Dissecting a hypoxia-related angiogenic gene signature for predicting prognosis and immune status in hepatocellular carcinoma. Front Oncol（Frontiers in Oncology）(IF:4.7). 2022 Aug 30;12:978050.
20.Lingwei Liu*, Jialang Zhuang*, Jizhou Tan*, Ting Liu, Wenzhe Fan, Yuanqing Zhang#, Jiaping Li#. Doxorubicin-Loaded UiO-66/Bi2S3 Nanocomposite-Enhanced Synergistic Transarterial Chemoembolization and Photothermal Therapy against Hepatocellular Carcinoma. ACS Applied Materials & Interfaces(IF:10.383). 2022 Feb 16;14(6):7579-7591.
21.Guixiong Zhang*, Wenzhe Fan, Hongyu Wang, Jie Wen, Jizhou Tan, Miao Xue, Jiaping Li#. Non-Apoptotic Programmed Cell Deathrelated Gene Signature Correlates with Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology(IF: 6.081). 2022 Feb 5;14:451-464.
22.Yiyang Tang*, Yanqin Wu, Miao Xue, Bowen Zhu, Wenzhe Fan, Jiaping Li#. A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Journal of Oncology(IF:4.501). 2022 Jan 24;2022:3822773. doi: 10.1155/2022/3822773
23.Hongyu Wang*, Guixiong Zhang*, Wenzhe Fan, Yanqin Wu, Jiang Zhang, Miao Xue, Yue Zhao , Wang Yao, Jiaping Li#. Clinical Significance of Peripheral Blood Lymphocyte Subtypes and Cytokines in Patients with Hepatocellular Carcinoma Treated with TACE. Cancer Management and Research(IF:3.602). 2022 Feb 5;14:451-464. doi: 10.2147/CMAR.S342527.
24.Miao Xue*, Yanqin Wu*, Bowen Zhu, Xinhua Zou, Wenzhe Fan, Jiaping Li#. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study. AMERICAN JOURNAL OF CANCER RESEARCH(IF:5.942).2021 Dec 15;11(12):6107-6118.
25.Xinhua Zou*, Wenzhe Fan, Xiao Xue, Jiaping Li#. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Management and Research.(IF:3.602).2021 May 18;13:4013-4029.
26.Fan Zou*, Jizhou Tan*, Ting Liu*, Bingfeng Liu, Yaping Tang, Hui Zhang#, Jiaping Li#. The CD39 + HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8 + T cells exhibit potent anti-HCC activity. Molecular Therapy(IF:12.91). 2021 May 5;29(5):1794-1807. doi: 10.1016/j.ymthe.2021.01.021.
27.Wenzhe Fan*, Jian Guo*, Bowen Zhu, Shutong Wang, Lei Yu, Wanchang Huang, Huishuang Fan, Fuliang Li, Yanqin Wu, Yue Zhao, Yu Wang, Miao Xue, Hongyu Wang, Jiaping Li#. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. European Radiology(IF:7.034). 2021 Nov;31(11):8291-8301. DOI: 10.1007/s00330-021-07834-9
28.Xinhua Zou*, Miao Xue, Jiaping Li#. Combined Use of Transjugular Intrahepatic Portosystemic Shunt and Transarterial Chemoembolization in the Treatment of Esophageal and Gastric Variceal Bleeding: A Retrospective Study of 80 Patients with Hepatocellular Carcinoma and Portal Hypertension. MEDICAL SCIENCE MONITOR(IF:3.386). 2021 Nov 29;27:e934436. doi: 10.12659/MSM.934436
29.Miao Xue*, Yanqin Wu*, Bowen Zhu, Xinhua Zou, Wenzhe Fan, Jiaping Li#. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study. AMERICAN JOURNAL OF CANCER RESEARCH(IF:5.942). 2021 Dec 15;11(12):6107-6118.
30.Ting Liu*, Jizhou Tan*, Minhao Wu*, Wenzhe Fan, Jialiang Wei, Bowen Zhu, Jian Guo, Shutong Wang, Penghui Zhou, Hui Zhang, Liangrong Shi, Jiaping Li#. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39 + CD8 + T cells. Gut(IF:31.793). 2021 Oct;70(10):1965-1977.doi: 10.1136/gutjnl-2020-322196. Epub 2020 Dec 1.
31.Jia Wen*, Yi Xie, Yingqiang Zhang, Jiazhen Li#, Jiaping Li#, Yan Zhang, Xinchang Lu, Yi,Zhang, Yongkui Liu, Tao Liu, Longqing Li. MACC1 Contributes to the Development of Osteosarcoma Through Regulation of the HGF/c-Met Pathway and Microtubule Stability. Frontiers in Cell and Developmental Biology(IF:6.081). 2020 Dec 23;8:825. doi.org/10.3389/fcell.2020.00825
32.Lixin Ke*, Rui Shen*, Wenzhe Fan*, Wenjie Hu, Shunli Shen, Shaoqiang Li, Ming Kuang, Lijian Liang, Jiaping Li#, Baogang Peng#, Yunpeng Hua#. The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinoma. ANNALS OF TRANSLATIONAL MEDICINE(IF:3.616). 2020 Nov;8(21):1402. doi: 10.21037/atm-20-2420.
33.Jialang Zhuang*, Jizhou Tan*, Chenglin Wu*, Jie Zhang, Ting Liu, Chunhai Fan, Jiaping Li#,Yuanqing Zhang#. Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy. Nucleic Acids Res(IF:19.16).2020 Sep 18;48(16):8870-8882.doi: 10.1093/nar/gkaa683.
34.Zhexuan Wang*, Enxin Wang*, Wei Bai*, Dongdong Xia*, Rong Ding*, Jiaping Li*, Qiuhe Wang, Lei Liu, Junhui Sun, Wei Mu, Hui Zhao, Xingnan Pan, Guoliang Shao, Xiaoli Zhu, Guowen Yin, Haibin Shi, Jianbing Wu, Zhengyu Lin, Shufa Yang, Jueshi Liu, Wenhui Wang, Xu Zhu, Yong Lv, Jing Li, Hui Chen, Wenjun Wang, Kai Li, Xulong Yuan, Tanlei Yu, Jie Yuan, Xiaomei Li, Jing Niu, Zhanxin Yin, Jielai Xia, Daiming Fan, s and Guohong Han. Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study. Liver Cancer(IF:12.43). 2020 Jun;9(3): 308–325. doi: 10.1159/000505692
35.Yingqiang Zhang*, Guihua Huang*, Hongfei Miao, Ze Song, Xiaoying Zhang, Wenzhe Fan, Yu Wang, Jiaping Li#, Yong Chen#. Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. Ther Adv Med Oncol(IF:5.485). 2020 Jul 23;12:1758835920937422. doi: 10.1177/1758835920937422.
36.Jialiang Wei*, Wei Cui*, Wenzhe Fan, Jiaping Li#. Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation. Front Oncol(IF:5.738). 2020 Aug 7;10:1285.doi: 10.3389/fonc.2020.01285.
37.Bowen Zhu*, Yanqin Wu, Lizhi Niu, Wang Yao, Miao Xue, Hongyu Wang, Jianyong Yang, Jiaping Li#and Wenzhe Fan#. Silencing SAPCD2 Represses Proliferation and Lung Metastasis of Fibrosarcoma by Activating Hippo Signaling Pathway. Front Oncol(IF:5.738). 2020 Dec 15;10:574383. doi: 10.3389/fonc.2020.574383.
38.Wang Yao*, Miao Xue*, Mingjian Lu*, Yu Wang, Yue Zhao, Yanqin Wu, Wenzhe Fan, Jiaping Li#. Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy. Front Oncol(IF:5.738). 2020 Dec 17;10:574668. doi: 10.3389/fonc.2020.574668. eCollection 2020.
39.Jiaping Li*, Wei Jiang*, Jinwang Wei*, Jianwei Zhang, Linbo Cai, Minjie Luo, Zhan Wang, Wending Sun, Shengzhou Wang, Chen Wang, Chun Dai, Jun Liu, Guan Wang, Jiping Wang, Qiang Xu#, Yanhong Deng#. Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors. J Transl Med(IF:8.44). 2020;18(1):293. doi: 10.1186/s12967-020-02449-y
40.Miao Xue*, Yanqin Wu*, Wenzhe Fan, Jian Guo, Jialiang Wei, Hongyu Wang, Jizhou Tan, Yu Wang, Wang Yao , Yue Zhao, Jiaping Li#. Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma. Cancer Res Treat(IF:4.802). 2020 Jul;52(3):925-937. doi: 10.4143/crt.2019.533.
41.Hongyu Wang*, Chuyang Lin*, Wenzhe Fan, Jiang Zhang, Yingqiang Zhang, Wang Yao , Jiaping Li#. Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancer Manag Res(IF:3.602). 2020 May 14;12:3433-3444. doi: 10.2147/CMAR.S245396.
42.Y-Q Wu*, W-Z Fan*, M Xue, J Guo, J-L Wei, Y Wang, W Yao, Y Zhao, J-P Li#. 25-OH-vitamin D Deficiency Identifies Poor Tumor Response in Hepatocellular Carcinoma Treated With Transarterial Chemoembolization. Clin Transl Oncol(IF:3.34). 2020 Jan;22(1):70-80. doi: 10.1007/s12094-019-02146-3.
43.Yao Wang*, Meng Yuqi*, Lu Mingjian, Fan Wenzhe, Huang Jinhua, Li Jiaping#, Zhu Zhihua#. Impact of type 2 diabetes mellitus on short-term and long-term outcomes of patients with esophageal squamous cell cancer undergoing resection: a propensity score analysis. CANCER COMMUNICATIONS(IF:15.283),2018;38(1):14. DOI:10.1186/s40880-018-0275-2
